logo-loader
viewGenetic Technologies

Genetic Technologies genetic test could determine those at high risk of contracting COVID-19

A vaccine for COVID-19 is expected to take a long time to develop and the company is confident its genetic test will be another bullet in the armoury to fight the virus in the meantime.

Genetic Technologies - Genetic Technologies genetic test could determine those at high risk of contracting COVID-19
The genetic test could take up to three months to develop

Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) is accelerating the development of a genetic test that will determine if people are at a high risk of contracting COVID-19. 

The test uses a polygenic risk score (PRS) to predict an individual’s risk of developing life-threatening complications should they become infected with COVID-19.

Genetic Technologies CEO Dr George Muchnicki said: "GENE has secured a data set of over 1,500 patients who experienced COVID-19 and we intend on leveraging our core expertise in predictive risk modelling, to analyse the early, available genomic and phenotypic data from those COVID-19 patients with a view to developing a comprehensive predictive model to identify those patients most likely to require hospitalization, should they become infected with the COVID-19 virus."

Predictive test design

Genetic Technologies chief scientific officer Dr Richard Allman said: "Our core strength is in the design and construction of novel risk algorithms for common, complex diseases.

“We anticipate that the design of a new predictive test will utilise similar concepts to those used in our existing core GeneType risk assessment products.

“We are fast-tracking analysis of the data set we have received and then we are commencing the development process with the aim of having sufficient understanding of that data to develop and validate a prototype test in the shortest time period possible.

“Of course, until we complete that analysis there is no guarantee that the genetic markers we are looking for will provide sufficient statistical evidence to support predictive risk modelling test."

The polygenic risk score (PRS) predicts an individual’s risk of developing life-threatening complications if they contract COVID-19

Estimated timeline

Dr Muchnicki said: "We anticipate approximately 3-month development timeline for the review of that data and the potential design of a predictive risk model and then we would need to obtain Clinical Laboratory Improvement Amendments (CLIA) and potentially other approvals of the laboratory-derived test."

Once developed, the test will have global application, however, the company acknowledges that there is no guarantee that GENE will be able to successfully produce a test that allows for the assessment of predictive risk in a timely manner and that if COVID-19 is effectively contained (or the risk of infection is materially diminished or eliminated) there may be no demand for the tests.

Validation of GeneType product

Two research and development studies are nearing completion for Genetic Technologies GeneType test for breast and colorectal cancer tests.

The results are expected to be submitted for publication in peer-reviewed medical journals in the next quarter and set the stage to progress the company’s plans to develop clinical utility evidence as well as driving physician acceptance of the tests.

The company has also completed development of a prototype test designed to incorporate a polygenic risk score in combination with a clinical risk algorithm to better predict the risk of developing Type-2 Diabetes.

The Melbourne laboratory is currently implementing the internal workflows and verification procedures prior to commercial launch.

The company's breast and colorectal cancer products are market ready

CIT platform agreement signed

Genetic Technologies has signed with its preferred Consumer Initiated Testing (CIT) platform provider to enable sales of tests to be initiated directly by consumers in the United States.

The company’s current CLIA and National Association of Testing Authorities (NATA) accredited laboratory will be utilised for the provision of tests across GeneType for Breast and GeneType for Colo-Rectal cancer and will have the capacity to provide additional tests as they come to market.

The platform is expected to go live within 60 days.

Board and management changes

The board has confirmed that Dr Jerzy Muchnicki will maintain his current position as interim CEO and current director Peter Rubinstein will assume the role of chairman.

GTG also welcomes a new chief operating officer in Stan Sack, who has spent 15 years in large listed entities in executive positions managing large business divisions.

Quick facts: Genetic Technologies

Price: 0.006 AUD

ASX:GTG
Market: ASX
Market Cap: $43.28 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Australian Vanadium confirms ‘exceptional’ vanadium extraction in test work

Australian Vanadium Ltd (ASX:AVL) (OTCMKTS:ATVVF) managing director Vincent Algar speaks to Proactive about recent pilot test-work conducted at the Australian Vanadium Project, which delivered leach extraction of up to 94.7%. The pilot-scale roast and leach testing has confirmed the...

1 day, 22 hours ago

4 min read